

FROM THE NEW EDITOR-IN-CHIEF

KENNETH I. KAITIN, PhD

Editor-in-Chief, *Drug Information Journal*

IT IS A TREMENDOUS honor to have been selected by the Drug Information Association Board of Directors to succeed Tom Teal as the new editor-in-chief of the *Drug Information Journal*. Over the past 10 years, I have had the pleasure of working with Tom as a member of the journal's editorial board. During that time I witnessed extraordinary growth in the *Drug Information Journal's* scholarship, breadth, and reach that flowed directly from Tom's remarkable leadership. My primary goal as the new editor-in-chief is to continue that growth and to further enhance the journal's reputation and stature.

The *Drug Information Journal* occupies a unique niche. Unlike other professional journals that have a relatively homogeneous readership, the *Drug Information Journal* has an extraordinarily diverse readership, which includes drug developers, regulators, policy makers, service providers, and academics. Like the drug development process itself, the *Drug Information Journal* provides a meeting place for a host of disciplines, including medicine, law, pharmacology, economics, statistics, marketing, and public policy. What unites the readership of the *Drug Information Journal* is a common interest in the discovery, development, regulation, and utilization of therapeutic and diagnostic medicines worldwide. While meeting the needs of this diverse group of disciplines and interests may be the *Drug Information Journal's* greatest chal-

lenge, the journal's global and diverse readership also represents its greatest strength.

During the coming year, you will begin to see several significant changes in the look and format of the *Drug Information Journal*. To increase readability and utility, the journal will be organized into separate sections devoted to studies that present original research findings, review articles, and methodological and technology oriented reports, as well as short communications and correspondence. In addition, the structure of the editorial board will be modified to include section editors, who will represent different areas. Section editors will identify important topics for publication and help solicit manuscripts for the journal. Finally, to expand the global reach and relevance of the *Drug Information Journal*, I will appoint a European associate editor, to ensure that important research, meetings, and workshops conducted in Europe receive adequate attention and coverage in the journal.

As the economic and political challenge of pharmaceutical innovation continues to increase, so too does the demand for solid research, quality reviews, and timely analyses. The *Drug Information Journal* is uniquely positioned to deliver. As the new editor-in-chief, I am committed to raising international recognition of the *Drug Information Journal* as a first-class professional journal and to helping it achieve a reputation for high quality scholarship that it so richly deserves.